According to the company’s exchange filing, the inspection was carried out between 17 November and 21 November 2025. Natco stated that the observations are procedural in nature and expressed confidence in addressing them comprehensively.

The company added that it remains committed to maintaining cGMP compliance and ensuring the supply of high-quality products to customers and patients worldwide.

NATCO Pharma, headquartered in Hyderabad, India, develops, manufactures and distributes generic and branded pharmaceuticals, specialty pharmaceuticals, active pharmaceutical ingredients and crop protection products.

The company’s consolidated net profit fell 23.5% to Rs 518.40 crore in Q2 FY26, compared with Rs 677.30 crore in Q2 FY25. Revenue from operations declined marginally to Rs 1,363 crore in Q2 FY26, compared with Rs 1,371.10 crore in Q2 FY25.